Solid Tumors – Page 6

Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α

Post author:
Post published:October 11, 2026
Post category:

Translational Candidate EGFR-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with metastatic breast cancer, especially HER2-low breast cancer Mechanism of Action EGFR-CAR_sIL15…

Next generation affinity-tuned CAR for prostate cancer

Post author:
Post published:October 11, 2026
Post category:

Translational Candidate A next generation cell therapy product that targets prostate cancer cells Area of Impact Prostate cancer Mechanism of Action The therapeutic candidate when expressed on the surface of…

Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma

Post author:
Post published:October 11, 2026
Post category:

Translational Candidate Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Area of Impact Glioblastoma is the most common malignant brain tumor, affecting approximately…

CAR-Tnm cell therapy for melanoma targeting TYRP-1

Post author:
Post published:October 11, 2026
Post category:

Translational Candidate Autologous naive/memory progenitor T cells genetically modified to express a chimeric antigen receptor targeting the Tyrosinase-related protein 1 Area of Impact Patient with melanoma, without response or with…

Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma

Post author:
Post published:October 11, 2026
Post category:

Translational Candidate Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Area of Impact Glioblastoma is the most common malignant brain tumor, affecting approximately…

Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer

Post author:
Post published:October 11, 2026
Post category:

Translational Candidate A clinically tested tumor-tropic neural stem cell (NSC) platform for effective distribution of oncolytic virotherapy to ovarian cancer metastases Area of Impact This NSC-delivered virotherapy approach will lead…

Placental Derived Natural Killer Cells to Target Solid Tumor Cancer Stem Cells (CSC)

Post author:
Post published:October 11, 2026
Post category:

Translational Candidate Placental-derived stem cells becoming a unique NK-like cell Area of Impact solid tissue cancers Mechanism of Action These expanded cells share many characteristics as NK cells but appear…

2nd Generation Vaccine for the Treatment of Glioblastoma

Post author:
Post published:October 11, 2026
Post category:

Translational Candidate It is the peptide LEEKKYNYVVVTDHC conjugated to KLH and used as an anti-cancer vaccine. Area of Impact This is a better optimized, more robust vaccine that aspires to…

SRN-101 AAV Immuno-Gene Therapy for High-Grade Glioma

Post author:
Post published:October 11, 2026
Post category:

Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma

Post author:
Post published:October 11, 2026
Post category:

Therapeutic Candidate or Device Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Indication Patients with MGMT unmethylated newly diagnosed GBM (Cohort 1), and…